The Brain‐Gut Axis in Parkinson's Disease Pathology
Open Access
- 29 March 2026
- journal article
- review article
- Published by Wiley in Comprehensive Physiology
- Vol. 16 (2) , e70137
Abstract
Parkinson's disease, characterized by the motor deficits that result from the loss of dopaminergic neurons in the Substantia Nigra pars compacta, is the second most common neurodegenerative disorder worldwide. Parkinson's disease is also commonly associated with severe non‐motor symptoms, including hyposmia and sleep disorders, as well as gastrointestinal dysfunction and dysregulation of the brain‐gut axis. Increasing evidence indicates that pathology in the “body‐first” subtype of Parkinson's disease may originate in the gastrointestinal (GI) tract and then spread to the brain via the vagus nerve. GI dysfunction may also arise, however, from “top‐down” or “brain‐first” mechanisms, reflecting bidirectional brain‐gut interactions. Systemic environmental factors, such as exposure to pesticides and heavy metals, are hypothesized to initiate this pathology and promote α‐synuclein (α‐syn) misfolding and the formation of Lewy Bodies. A growing body of evidence suggests, however, that oxidative stress and glial activation may emerge in the enteric nervous system and the dorsal motor nucleus of the vagus long before the onset of neurodegeneration, and that these early changes may be sufficient to drive the retrograde spread of pathology to higher brain regions. The purpose of this review is to discuss the progression of PD pathology across the brain‐gut axis, providing insights into the contribution of oxidative stress and glial activation to neuronal loss, and highlighting the importance of these mechanisms for potential therapeutic intervention at the earliest stages of PD.Keywords
Funding Information
- National Institutes of Health (124098)
- U.S. Department of War (W81XWH2110915)
This publication has 134 references indexed in Scilit:
- MPTP‐Induced Hypoactivity in Mice: Reversal by L‐DopaBasic & Clinical Pharmacology & Toxicology, 1990
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990
- A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia NigraJournal of Neurochemistry, 1989
- Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brainsNeurology, 1988
- Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexusesActa Neuropathologica, 1988
- Sympathetic control of motility, fluid transport, and transmural potential difference in the rabbit ileumAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 1987
- LIPID PEROXIDATION AS CAUSE OF NIGRAL CELL DEATH IN PARKINSON'S DISEASEThe Lancet, 1986
- The complexity and diversity of synaptic transmission in the prevertebral sympathetic gangliaProgress in Neurobiology, 1985
- Chronic parkinsonism secondary to intravenous injection of meperidine analoguesPsychiatry Research, 1979
- 6-Hydroxydopamine: Evidence for Superoxide Radical as an Oxidative IntermediateScience, 1973